LEAP-008 (NCT03976375) was an open-label, randomized, phase 3 study of lenvatinib plus pembrolizumab versus docetaxel for metastatic NSCLC that progressed on antiâ€’programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) therapy and platinum-containing chemotherapy.
